Heart and coronary artery protection in patients with mediastinal Hodgkin lymphoma treated with intensity-modulated radiotherapy: Dose constraints to virtual volumes or to organs at risk?

Radiotherapy and Oncology

Volumn 87, Issue 1, 2008, Pages 82-88

  Ghalibafian, Mithra ^a   Beaudre, Anne ^a   Girinsky, Theodore ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Hodgkin lymphoma; Intensity modulated radiotherapy; Mediastinal masses; Virtual volumes

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINCRISTINE;

ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CORONARY ARTERY; HEART PROTECTION; HODGKIN DISEASE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LYMPH NODE; PRIORITY JOURNAL; RADIATION DOSE; RISK;

ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CORONARY VESSELS; HEART; HODGKIN DISEASE; HUMANS; MEDIASTINAL NEOPLASMS; RADIATION INJURIES; RADIATION PROTECTION; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 41849102683     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2007.10.016     Document Type: Article

References (15)

1. Aleman B.M., van den Belt-Dusebout A.W., Klokman W.J., Van't Veer M.B., Bartelink H., and van Leeuwen F.E. Long-term cause-specific mortality of patients treated for Hodgkin disease. J Clin Oncol 21 (2003) 3431-3439
2. Constine L.S., Schwartz R.G., Savage D.E., King V., and Muhs A. Cardiac function, perfusion, and morbidity in irradiated long-term survivors of Hodgkin's disease. Int J Radiat Oncol Biol Phys 39 (1997) 897-906
3. Diehl V., Brillant C., Engert A., et al. HD10: Investigating reduction of combined modality treatment intensity in early stage Hodgkin's lymphoma. Interim analysis of a randomized trial of the German Hodgkin Study Group (GHSG) [Abstract]. J Clin Oncol 23 (2005) 561S
4. Dogan N., Leybovich L.B., King S., Sethi A., and Emami B. Improvement of treatment plans developed with intensity-modulated radiation therapy for concave-shaped head and neck tumors. Radiology 223 (2002) 57-64
5. Esik O., Bortfelt T., Bendl R., Nemeth G., and Schlegel W. Inverse radiotherapy planning for a concave-convex PTV in cervical and upper mediastinal regions. Strahlenter Onkol 173 (1997) 193-200
6. Girinsky T., Pichenot C., Beaudre A., Ghalibafian M., and Lefkopoulos D. Is intensity-modulated radiotherapy better than conventional radiation treatment and 3D conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease? Is there a role for beam orientation optimization and dose constraints assigned to virtual volumes?. Int J Radiat Oncol Biol Phys 64 (2006) 218-226
7. Girinsky T., van der Maazen R., Specht L., et al. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 79 (2006) 270-277
8. Goodman K.A., Toner S., Hunt M., Wu E.J., and Yahalom J. Intensity-modulated radiotherapy for lymphoma involving the mediastinum. Int J Radiat Oncol Biol Phys 62 (2005) 198-206
9. Hancock S.L., Tucker M.A., and Hoppe R.T. Factors affecting late mortality from heart disease after treatment of Hodgkin disease. JAMA 270 (1993) 1949-1955
10. ICRU. Prescribing, recording and reporting photon beam therapy. Report 50, International Commission on Radiation Units and Measurements. Washington, DC, 1993.
11. Klimm B.C., Engert A., and Brillant C. Comparison of BEACOPP and ABVD chemotherapy in intermediate stage Hodgkin lymphoma: results of the fourth interim analysis of the HD-11 trial of the GHSG. Proc Am Soc Clin Oncol 124 (2005) [Abstract 6507]
12. Ng A.K., Bernardo M.P., Weller E., et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin disease treated at age 50 or younger. J Clin Oncol 20 (2002) 2101-2108
13. Noordijk E.M., Thomas J., Ferme C.H., et al. First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable and unfavorable early stage Hodgkin lymphoma. Proc Am Soc Clin Oncol (2005) 124 [Abstract 6505]
14. Schultz-Hector S., and Trott K.R. Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data. Int J Radiat Oncol Biol Phys 67 (2007) 10-18
15. Wu Q., Manning M., Schmidt-Ullrich R., and Mohan R. The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments of head and neck cancers: a treatment design study. Int J Radiat Oncol Biol Phys 46 (2000) 195-205